Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1450-1463

  Klyuchnikov, Evgeny ^a   Asenova, Svetlana ^a   Kern, Wolfgang ^b   Kilinc, Gkhan ^a   Ayuk, Francis ^a   Wiedemann, Bettina ^a   Lioznov, Michael ^a   Freiberger, Petra ^a   Zalyalov, Yuriy ^c   Zander, Axel Rolf ^a   Krger, Nicolaus ^a   Bacher, Ulrike ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c Raisa Gorbacheva Memorial Institute for Pediatric Hematology and Transplantology   (Russian Federation)

Author keywords

acute myeloid leukemia (AML); allogeneic stem cell transplant (allo SCT); Immune reconstitution; lymphocyte populations

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BUSULFAN; CD19 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SELECTION; CHILD; CLINICAL EVALUATION; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; PARAMETER; POSTOPERATIVE INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RISK MANAGEMENT; SCHOOL CHILD; SEPSIS; SURGICAL MORTALITY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM; IMMUNOPHENOTYPING; INFANT; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955435307     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.496015     Document Type: Article

References (58)

1. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008;30:425-437.
2. Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand. Blood 2004;103: 3860-3868.
3. Vitale M, Caruso A, Licenziati S, et al. Differential production of IFN-gamma, analyzed at the single-cell level, by specific subsets of human NK and T cells from healthy and HIV(+) subjects. Cytometry 2000;39:189-194.
4. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380-3389.
5. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood 2008;112:914-915.
6. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
7. Leung W, Iyengar R, Leimig T, Holladay MS, Houston J, Handgretinger R. Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer Immunol Immunother 2005;54:389-394.
8. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-440.
9. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994;84:2221-2228.
10. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995;16:413-425.
11. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007;19:318-330.
12. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993;12:387-398.
13. Suzuki I, Milner EC, Glas AM, et al. Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest. Blood 1996;87:1873-1880.
14. Glas AM, van Montfort EH, Storek J, et al. B-cellautonomous somatic mutation deficit following bone marrow transplant. Blood 2000;96:1064-1069.
15. Gerritsen EJ, van Tol MJ, van't Veer MB, et al. Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation. Blood 1994;84:4374-4382.
16. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-2779.
17. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5675-5687.
18. Saliba RM, Komanduri KV, Giralt S, et al. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 2009;43:685-692.
19. Eyrich M, Wollny G, Tzaribaschev N, et al. Onset of thymic recovery and plateau of thymic output are differentially regulated after stem cell transplantation in children. Biol Blood Marrow Transplant 2005;11:194-205.
20. Jimenez M, Martinez C, Ercilla G, et al. Clinical factors influencing T-cell receptor excision circle (TRECs) counts following allogeneic stem cell transplantation in adults. Transpl Immunol 2006;16:52-59.
21. Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 2002;73:1154-1158.
22. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006;12:1176-1187.
23. Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001;29: 458-470.
24. Ageitos AG, Varney ML, Bierman PJ, Vose JM,Warkentin PI, Talmadge JE. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. Bone Marrow Transplant 1999;23:63-69.
25. Ino K, Singh RK, Talmadge JE. Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol 1997;61:583-591.
26. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factormobilized blood products: a mechanism for monocytemediated suppression of T-cell proliferation. Blood 1998;92: 215-222.
27. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005;19:822-828.
28. Lee SH, Lee MH, Lee JH, et al. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant 2005;11:122-128.
29. Nakamura R, Auayporn N, Smith DD, et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008;14:449-457.
30. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009;114:2606-2616.
31. van der Vliet H, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol 2008;180:7287-7293.
32. Gerosa F, Gobbi A, Zorzi P, et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005;174:727-734.
33. Maris M, Boeckh M, Storer B, et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003;31:941-952.
34. Petersen SL, Ryder LP, Bjork P, et al. A comparison of T-, B-and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant 2003;32:65-72.
35. Busca A, Lovisone E, Aliberti S, et al. Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 2003;8: 303-311.
36. Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-249.
37. Jimenez M, Ercilla G, Martinez C. Immune reconstitution after allogeneic stem cell transplantation with reducedintensity conditioning regimens. Leukemia 2007;21:1628-1637.
38. Schulenburg A, Fischer M, Kalhs P, et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leuk Lymphoma 2005;46:1755-1760.
39. Chao NJ, Liu CX, Rooney B, et al. Nonmyeloablative regimen preserves 'niches' allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant 2002;8:249-256.
40. Jimenez M, Martinez C, Ercilla G, et al. Reduced-intensity conditioning regimen preserves thymic function in the early period after hematopoietic stem cell transplantation. Exp Hematol 2005;33:1240-1248.
41. Barrios M, Jimenez-Velasco A, Roman-Gomez J, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003;88:801-810.
42. Kumar S, Chen MG, Gastineau DA, et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003;17:1865-1870.
43. Chakrabarti S, Brown J, Guttridge M, Pamphilon DH, Lankester A, Marks DI. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited Tcell addback. Bone Marrow Transplant 2003;32:23-30.
44. Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;34: 43-49.
45. Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. et al. Rapid helper T-cell recovery above 200x106/L at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006;37: 1119-1128.
46. Novitzky N, Davison GM, Hale G, Waldmann H. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome. Transplantation 2002;74:1551-1559.
47. Koehl U, Bochennek K, Zimmermann SY, et al. Immune recovery in children undergoing allogeneic stem cell transplantation: absolute CD8+CD3+ count reconstitution is associated with survival. Bone Marrow Transplant 2007; 39: 269-278.
48. Afzal S, Ishaqi MK, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia -update study. Bone Marrow Transplant 2009;44:799-804.
49. Barrett AJ, Rezvani K, Solomon S, et al. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program 2003:350-371.
50. Leitenberg D, Rappeport JM, Smith BR, B-cell precursor bone marrow reconstitution after bone marrow transplantation, Am J Clin Pathol 1994;102;231-236
51. Takahashi T, Chiba S, Matsumura T, Hirai H. A case of severe B cell deficiency after allogeneic stem cell transplantation. Bone Marrow Transplant 2002;30:397-400.
52. Godfrey DI, Berzins SP. Control points in NKT-cell development. Nat Rev Immunol 2007;7:505-518.
53. Hayday AC. Gamma/delta T cells and the lymphoid stresssurveillance response. Immunity 2009;31:184-196.
54. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815-1822.
55. Long GD, Laughlin M, Madan B, et al. Unrelated umbilical cord blood transplantation in adult patients. Biol Blood Marrow Transplant 2003;9:772-780.
56. Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versusleukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 2008;41:245-252.
57. Saito T, Kanda Y, Nakai K, et al. Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. Bone Marrow Transplant 2003;32:601-608.
58. Bahceci E, Epperson D, Douek DC, Melenhorst JJ, Childs RC, Barrett AJ. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. Br J Haematol 2003;122:934-943.